GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT01545440
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT01545453
A Study of MCAF5352A in Healthy Volunteers
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01540760
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT01522664
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01519804
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Drug: PlaceboDrug: cisplatin/carboplatin
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT01496742
A Study of RG7667 in Healthy Volunteers
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT01496755
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 501
- Registration Number
- NCT01493843
- Locations
- 🇺🇸
Franklin Square Hospital, Baltimore, Maryland, United States
🇦🇺Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia
🇭🇺Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: [14C]-GDC-0980
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01487239
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT01485861
- Locations
- 🇺🇸
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
🇺🇸Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
🇨🇿Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia
© Copyright 2025. All Rights Reserved by MedPath